SCHEMBL1608256

SCHEMBL1608256

O=C(NO)c1ccc2ncn(CCOc3ccccc3F)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.47
HDAC1 Q13547 3/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 3/20 0.45
MAPT P10636 3/20 0.45
POLB P06746 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RAB9A P51151 5/20 0.45
GAA P10253 1/20 0.45
CNR1 P21554 1/20 0.43
IDO1 P14902 2/20 0.43
NPC1 O15118 3/20 0.42
PKM P14618 1/20 0.42
HDAC4 P56524 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1608313 0.92 HDAC6 (0.43) HDAC6HDAC1SMN1; SMN2HTTLMNA
SCHEMBL1608591 0.91 CNR1 (0.43) HDAC6HDAC1SMN1; SMN2HTTLMNA
SCHEMBL1607539 0.87 LMNA (0.62) HDAC6HDAC1SMN1; SMN2HTTLMNA
SCHEMBL1607816 0.85 SMN1; SMN2 (0.53) HDAC6HDAC1SMN1; SMN2HTTLMNA
SCHEMBL1608583 0.83 SMN1; SMN2 (0.48) HDAC6HDAC1SMN1; SMN2HTTLMNA
SCHEMBL1608224 0.82 HDAC6 (0.48) HDAC6HDAC1SMN1; SMN2HTTRAB9A
SCHEMBL1607795 0.82 HDAC6 (0.49) HDAC6HDAC1SMN1; SMN2HTTLMNA
SCHEMBL1609007 0.82 HDAC6 (0.48) HDAC6HDAC1SMN1; SMN2HTTLMNA
SCHEMBL1608357 0.80 PPARG (0.57) HDAC6HDAC1CNR1IDO1HDAC4
SCHEMBL1608435 0.79 SMN1; SMN2 (0.51) HDAC6HDAC1SMN1; SMN2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE PHARMACYCLICS LLC 2015-11-12 US disclosed
US-8906954-B2 Selective inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2014-12-09 US disclosed
US-20140004174-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE PHARMACYCLICS, INC. (US) 2014-01-02 US disclosed
US-8466193-B2 Selective inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2013-06-18 US disclosed
US-20110081409-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE PHARMACYCLICS LLC 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081409-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE HDAC8, HDAC1, HDAC11 HDAC6 11/4885HDAC1 2/4885SMN1; SMN2 1689/4885
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE HDAC8, HDAC1, HDAC5 HDAC6 11/4885HDAC1 2/4885SMN1; SMN2 1847/4885
US-20140004174-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE HDAC8, HDAC1, HDAC11 HDAC6 11/4885HDAC1 2/4885SMN1; SMN2 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.